344 related articles for article (PubMed ID: 20813200)
21. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
22. Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.
Cheng W; Hu Y; Sheng R
Curr Med Chem; 2014; 21(38):4374-404. PubMed ID: 25245375
[TBL] [Abstract][Full Text] [Related]
23. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
24. RANKL Signaling and ErbB Receptors in Breast Carcinogenesis.
Zoi I; Karamouzis MV; Adamopoulos C; Papavassiliou AG
Trends Mol Med; 2016 Oct; 22(10):839-850. PubMed ID: 27567286
[TBL] [Abstract][Full Text] [Related]
25. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
26. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract][Full Text] [Related]
27. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
28. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.
Penington DJ; Bryant I; Riese DJ
Cell Growth Differ; 2002 Jun; 13(6):247-56. PubMed ID: 12114214
[TBL] [Abstract][Full Text] [Related]
29. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells.
Egeblad M; Jäättelä M
Int J Cancer; 2000 Jun; 86(5):617-25. PubMed ID: 10797281
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of resistance to HER family targeting antibodies.
Kruser TJ; Wheeler DL
Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
[TBL] [Abstract][Full Text] [Related]
31. In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches.
Simond AM; Muller WJ
Adv Cancer Res; 2020; 147():189-228. PubMed ID: 32593401
[TBL] [Abstract][Full Text] [Related]
32. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
[TBL] [Abstract][Full Text] [Related]
33. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
36. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
Jin Q; Esteva FJ
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
38. HER3 signaling and targeted therapy in cancer.
Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
[TBL] [Abstract][Full Text] [Related]
39. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
40. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]